Reckitt Benckiser has issued a voluntary recall for Mead Johnson Nutrition brand's baby formula powder. The U.S. Food and Drug Administration (US FDA) said that the health and nutrition firm decided to recall some batches of the said product due to possible bacterial contamination.
As per CNBC, the affected infant formula is being sold in the market as Nutramigen Powder. This infant formula is specially made for babies allergic to cow's milk. The recalled batches were produced in June and distributed to stores in the summer.
Recalled Batches of Nutramigen Powder
Reckitt Benckiser said that so far, it has not received any reports of illnesses or adverse effects related to the recalled Nutramigen Powder. However, the company is urging customers who have bought the milk formula to check the can to see if what they purchased is included in the batches that may have been contaminated.
The company said that the affected products have these batch numbers and their corresponding can sizes: ZL3FHG, 12.6 oz cans, ZL3FMH, 12.6 oz cans, ZL3FPE, 12.6 oz cans, ZL3FQD, 12.6 oz cans, ZL3FRW, 19.8 oz cans, and ZL3FXJ, 12.6 oz cans.
Adverse Effects of Bacterial Infection
Fox Business says the total number of the affected Nutramigen infant powder is about 675,030 cans. The FDA warned on Sunday, Dec. 31, that they may be contaminated with Cronobacter sakazakii.
The National Food Administration further said that the milk formula was made at a production facility in Michigan. The bacteria in the product potentially cause severe infections such as meningitis and sepsis. The FDA listed jaundice, irritability, temperature change, poor feeding, trouble breathing, and unusual movements as the common symptoms of the infection.
Meanwhile, the announcement stressed, "No other U.S. distributed Nutramigen batches or other Reckitt products are impacted."
Photo by: Reckltt Press Release


China Automakers Accelerate Global Expansion as Domestic Car Sales Slump
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal
SpaceX Shares Surge as Wall Street Backs AI Growth Potential
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 



